Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

About Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: N/A
Symbol: NASDAQ:AGIO
CUSIP: N/A
Web: www.agios.com

Capitalization:

Market Cap: $2.67 billion
Outstanding Shares: 48,391,000

Average Prices:

50 Day Moving Avg: $57.25
200 Day Moving Avg: $52.43
52 Week Range: $35.84 - $67.74

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -7.64
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $53.49 million
Price / Sales: 49.86
Book Value: $10.53 per share
Price / Book: 5.23

Profitability:

EBIDTA: ($266,250,000.00)
Net Margins: -502.12%
Return on Equity: -68.15%
Return on Assets: -41.17%

Debt:

Current Ratio: 6.46%
Quick Ratio: 6.46%

Misc:

Average Volume: 523,214 shs.
Beta: 1.94
Short Ratio: 16.59

Frequently Asked Questions for Agios Pharmaceuticals (NASDAQ:AGIO)

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by $0.21. The company earned $11.30 million during the quarter, compared to analysts' expectations of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business's quarterly revenue was up 62.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.47) EPS. View Agios Pharmaceuticals' Earnings History.

When will Agios Pharmaceuticals make its next earnings announcement?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Agios Pharmaceuticals.

Where is Agios Pharmaceuticals' stock going? Where will Agios Pharmaceuticals' stock price be in 2017?

10 equities research analysts have issued twelve-month target prices for Agios Pharmaceuticals' shares. Their forecasts range from $57.00 to $90.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $74.75 in the next twelve months. View Analyst Ratings for Agios Pharmaceuticals.

What are analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:

1. Cann analysts commented, "This dinner and discussion with management, experts, and investors offered an update on AG-120 and an in-depth look at AG-221. Takeaways for AG-221 focused on outcomes and commercial use. AG-221 was found to have remarkable outcomes, especially in light of the difficult-to-treat population in the study. The enthusiasm expressed by Drs." (6/11/2017)
2. According to Zacks Investment Research, "Agios's shares have outperformed the Medical-Products industry so far this year. As a development-stage company, Agios depends heavily on Celgene for revenues. However, the collaboration with Celgene is encouraging as it provides Agios funds in the form of upfront, regulatory and commercial milestone payments plus royalties. In terms of the company’s pipeline, most of the candidates are in mid and early stages of development and thus, several years away from entering the market. Moreover, the decision to discontinue the development of AG-519 is disappointing. Stiff competition is another matter of concern for the company. Estimates have been going down lately ahead of the company’s Q1 earnings release. The company has mixed record of earnings surprises in recent quarters." (4/28/2017)
3. Cowen and Company analysts commented, "Agios ended 2016 with $574MM in cash, enough to last through 2018." (2/16/2017)

Who are some of Agios Pharmaceuticals' key competitors?

Some companies that are related to Agios Pharmaceuticals include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), AveXis (AVXS), Juno Therapeutics (JUNO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT), Loxo Oncology (LOXO), Axovant Sciences (AXON), Prothena Corporation PLC (PRTA), Aerie Pharmaceuticals (AERI), NovoCure Limited (NVCR) and Halozyme Therapeutics (HALO).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:

David P. Schenkein M.D., President, Chief Executive Officer, Director
Andrew Hirsch, Chief Financial Officer
Scott Biller Ph.D., Chief Scientific Officer
Christopher Bowden M.D., Chief Medical Officer
Steven L. Hoerter, Chief Commercial Officer
Lewis Clayton Cantley Ph.D., Director
David Scadden M.D., Director
Paul J. Clancy, Independent Director
Ian T. Clark, Independent Director
Kaye I. Foster-Cheek, Independent Director

Who owns Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), Vanguard Group Inc. (6.67%), Capital International Investors (6.47%), BB Biotech AG (5.95%), BlackRock Inc. (5.55%) and State Street Corp (2.69%). Company insiders that own Agios Pharmaceuticals stock include Celgene European Investment Co, David P Schenkein, Glenn Goddard, John Duncan Higgons, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Institutional Ownership Trends for Agios Pharmaceuticals.

Who sold Agios Pharmaceuticals stock? Who is selling Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Capital Guardian Trust Co., Columbus Circle Investors, Quantitative Investment Management LLC, JPMorgan Chase & Co., Fiera Capital Corp, Nationwide Fund Advisors and Paradigm Asset Management Co. LLC. Company insiders that have sold Agios Pharmaceuticals stock in the last year include David P Schenkein, Lewis Clayton Jr Cantley, Robert Nelsen and Scott Biller. View Insider Buying and Selling for Agios Pharmaceuticals.

Who bought Agios Pharmaceuticals stock? Who is buying Agios Pharmaceuticals stock?

Agios Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., BlackRock Inc., Janus Henderson Group PLC, First Trust Advisors LP, Capital International Investors, PDT Partners LLC and AXA. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy Agios Pharmaceuticals stock?

Shares of Agios Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of Agios Pharmaceuticals stock can currently be purchased for approximately $55.11.

MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		198 (Vote Outperform)
Underperform Votes:		196 (Vote Underperform)
Total Votes:		394

MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Hold Rating, 9 Buy Ratings
Consensus Rating:	Buy (Score: 2.90)
Consensus Price Target:	$74.75 (35.64% upside)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
8/10/2017	Oppenheimer Holdings, Inc.	Reiterated Rating	Outperform	$75.00 -> $83.00	Low
8/10/2017	Needham & Company LLC	Boost Price Target	Buy -> Buy	$54.00 -> $72.00	Medium
8/8/2017	Canaccord Genuity	Set Price Target	Buy	$90.00	Low
8/8/2017	SunTrust Banks, Inc.	Reiterated Rating	Buy -> Buy	$68.00 -> $80.00	Low
8/2/2017	Leerink Swann	Upgrade	Market Perform -> Outperform	$50.00 -> $80.00	High
8/1/2017	Janney Montgomery Scott	Reiterated Rating	Hold		High
6/11/2017	Cann	Reiterated Rating	Buy	$75.00	Medium
4/18/2017	Credit Suisse Group	Reiterated Rating	Outperform	$61.00	High
2/16/2017	Cowen and Company	Reiterated Rating	Buy		N/A
1/17/2017	CIBC	Upgrade	Market Perform -> Outperform		N/A
8/19/2016	BTIG Research	Initiated Coverage	Neutral		N/A
8/10/2016	Goldman Sachs Group, Inc. (The)	Reiterated Rating	Neutral	$46.00	N/A
6/13/2016	J P Morgan Chase & Co	Upgrade	Neutral -> Overweight	$50.00 -> $62.00	N/A
11/9/2015	Roth Capital	Lower Price Target	Neutral	$114.00 -> $75.00	N/A

(Data available from 8/21/2015 forward)

Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)

Earnings by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Earnings History by Quarter for Agios Pharmaceuticals (NASDAQ AGIO)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/1/2017		($1.78)					N/A
8/8/2017	Q2 2017	($1.57)	($1.78)	$10.68 million	$11.30 million	View	Listen
5/4/2017	Q1 2017	($1.80)	($1.56)	$9.65 million	$10.51 million	View	Listen
2/16/2017	Q416	($1.51)	($1.34)	$10.89 million	$22.65 million	View	Listen
11/3/2016	Q316	($1.52)	($1.63)	$7.82 million	$8.98 million	View	Listen
8/4/2016	Q216	($0.48)	($1.47)	$39.62 million	$6.98 million	View	Listen
5/5/2016	Q116	($0.79)	($0.61)	$20.94 million	$31.30 million	View	Listen
2/18/2016	Q415	($0.27)	($1.08)	$28.78 million	$6.22 million	View	Listen
11/5/2015	Q315	($0.89)	($1.07)	$17.21 million	$5.80 million	View	Listen
8/6/2015	Q215	($0.46)	($0.85)	$25.75 million	$13.20 million	View	Listen
5/7/2015	Q115	($0.86)	($0.13)	$10.86 million	$34.20 million	View	Listen
2/17/2015	Q414	($0.55)	($0.76)	$10.94 million	$14.64 million	View	Listen
11/7/2014	Q314	($0.53)	$0.10	$8.45 million	$33.90 million	View	Listen
8/7/2014	Q2	($0.47)	($0.54)	$11.00 million	$8.41 million	View	Listen
5/8/2014	Q1	($0.37)	($0.39)	$7.19 million	$8.41 million	View	Listen
3/6/2014	Q4	($0.34)	($0.40)	$6.19 million	$6.70 million	View	Listen
11/7/2013		($0.28)	($0.47)			View	Listen

(Data available from 1/1/2011 forward)

Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

2017 EPS Consensus Estimate: ($7.07)
2018 EPS Consensus Estimate: ($7.28)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	3	($1.86)	($1.78)	($1.81)
Q2 2017	3	($1.91)	($1.48)	($1.73)
Q3 2017	3	($1.99)	($1.50)	($1.76)
Q4 2017	3	($2.04)	($1.52)	($1.78)
Q1 2018	1	($2.31)	($2.31)	($2.31)
Q2 2018	1	($2.31)	($2.31)	($2.31)
Q3 2018	1	($2.45)	($2.45)	($2.45)
Q4 2018	1	($0.21)	($0.21)	($0.21)

(Data provided by Zacks Investment Research)

Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Agios Pharmaceuticals (NASDAQ:AGIO)

Insider Ownership Percentage: 10.55%
Institutional Ownership Percentage: 83.13%

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Insider Trades by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/2/2017	David P Schenkein	CEO	Sell	27,000	$59.95	$1,618,650.00
8/2/2017	Scott Biller	Insider	Sell	23,146	$59.60	$1,379,501.60
7/20/2017	Lewis Clayton Jr. Cantley	Director	Sell	9,000	$56.36	$507,240.00
7/19/2017	Lewis Clayton Jr. Cantley	Director	Sell	3,500	$56.14	$196,490.00
7/7/2017	Scott Biller	Insider	Sell	2,146	$55.00	$118,030.00
7/3/2017	David P Schenkein	CEO	Sell	3,000	$51.18	$153,540.00
6/21/2017	Scott Biller	Insider	Sell	4,292	$55.00	$236,060.00
6/14/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,000	$50.87	$101,740.00
6/7/2017	David P Schenkein	CEO	Sell	3,000	$50.02	$150,060.00
5/25/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$47.10	$95,895.60
5/1/2017	David P Schenkein	CEO	Sell	3,000	$50.06	$150,180.00
4/24/2017	Celgene European Investment Co	Major Shareholder	Buy	624,575	$49.50	$30,916,462.50
4/18/2017	Lewis Clayton Jr. Cantley	Director	Sell	5,090	$54.37	$276,743.30
4/17/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$55.24	$112,468.64
4/3/2017	David P Schenkein	CEO	Sell	3,000	$58.62	$175,860.00
4/3/2017	Scott Biller	Insider	Sell	2,146	$58.03	$124,532.38
3/23/2017	Lewis Clayton Jr. Cantley	Director	Sell	2,036	$53.11	$108,131.96
3/20/2017	Scott Biller	Insider	Sell	6,438	$55.00	$354,090.00
3/6/2017	Robert Nelsen	Director	Sell	40,599	$50.84	$2,064,053.16
2/28/2017	Robert Nelsen	Director	Sell	243,082	$49.36	$11,998,527.52
2/23/2017	Robert Nelsen	Director	Sell	135,364	$49.37	$6,682,920.68
2/16/2017	David P Schenkein	CEO	Sell	6,000	$50.01	$300,060.00
10/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$48.94	$122,545.76
10/5/2016	Scott Biller	Insider	Sell	5,000	$55.00	$275,000.00
9/28/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$54.00	$33,858.00
9/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$54.15	$33,952.05
9/20/2016	Scott Biller	Insider	Sell	5,000	$50.00	$250,000.00
8/30/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$36.81	$23,079.87
8/29/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$37.81	$23,706.87
7/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$42.80	$107,171.20
7/25/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$41.85	$26,239.95
6/28/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$41.88	$104,867.52
6/27/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$40.37	$25,311.99
6/8/2016	Scott Biller	Insider	Sell	27,500	$65.00	$1,787,500.00
5/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$51.69	$129,431.76
4/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$53.44	$133,813.76
4/25/2016	Lewis Clayton Jr. Cantley	Director	Sell	627	$55.00	$34,485.00
3/30/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$37.19	$93,123.76
2/26/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$37.90	$94,901.60
1/29/2016	Lewis Clayton Jr. Cantley	Director	Sell	2,504	$42.93	$107,496.72
12/29/2015	Lewis Clayton Jr. Cantley	Director	Sell	10,664	$64.93	$692,413.52
12/15/2015	John Duncan Higgons	COO	Sell	20,000	$50.09	$1,001,800.00
11/17/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,408	$59.83	$562,880.64
11/16/2015	John Duncan Higgons	COO	Sell	20,000	$61.51	$1,230,200.00
11/2/2015	Scott Biller	insider	Sell	5,500	$77.12	$424,160.00
10/23/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$61.16	$593,496.64
10/15/2015	John Duncan Higgons	COO	Sell	20,000	$71.04	$1,420,800.00
9/30/2015	Scott Biller	insider	Sell	5,500	$70.44	$387,420.00
9/25/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$83.25	$807,858.00
9/24/2015	Glenn Goddard	SVP	Sell	6,000	$85.97	$515,820.00
9/15/2015	John Duncan Higgons	COO	Sell	20,000	$91.11	$1,822,200.00
8/18/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$94.94	$921,297.76
8/17/2015	John Duncan Higgons	COO	Sell	20,000	$92.24	$1,844,800.00
7/23/2015	Glenn Goddard	SVP	Sell	7,000	$120.45	$843,150.00
7/20/2015	Scott Biller	Insider	Sell	5,500	$113.87	$626,285.00
7/17/2015	Glenn Goddard	SVP	Sell	13,000	$113.71	$1,478,230.00
7/16/2015	John Duncan Higgons	COO	Sell	20,000	$114.02	$2,280,400.00
7/16/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$114.28	$1,108,973.12
6/25/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$105.13	$1,020,181.52
6/15/2015	John Duncan Higgons	COO	Sell	7,000	$105.23	$736,610.00
6/8/2015	Scott Biller	Insider	Sell	5,500	$121.85	$670,175.00
6/1/2015	Christopher Bowden	Insider	Sell	5,000	$120.67	$603,350.00
6/1/2015	David P Schenkein	CEO	Sell	13,000	$120.67	$1,568,710.00
5/27/2015	David P Schenkein	CEO	Sell	8,929	$120.05	$1,071,926.45
5/27/2015	Glenn Goddard	SVP	Sell	2,171	$120.05	$260,628.55
5/20/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$116.64	$1,131,874.56
5/15/2015	John Duncan Higgons	COO	Sell	7,417	$112.89	$837,305.13
5/12/2015	David P Schenkein	CEO	Sell	5,200	$110.02	$572,104.00
5/8/2015	David P Schenkein	CEO	Sell	3,900	$101.32	$395,148.00
5/7/2015	Scott Biller	Insider	Sell	5,500	$96.32	$529,760.00
4/24/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$105.15	$1,020,375.60
4/15/2015	John Duncan Higgons	COO	Sell	6,583	$99.54	$655,271.82
4/13/2015	David P Schenkein	CEO	Sell	3,900	$100.03	$390,117.00
4/8/2015	Scott Biller	Insider	Sell	5,500	$97.64	$537,020.00
4/1/2015	David P Schenkein	CEO	Sell	3,900	$92.54	$360,906.00
3/27/2015	Lewis Clayton Jr. Cantley	Director	Sell	9,704	$93.58	$908,100.32
3/16/2015	Glenn Goddard	SVP	Sell	10,000	$106.24	$1,062,400.00
3/16/2015	John Duncan Higgons	COO	Sell	7,000	$106.24	$743,680.00
3/16/2015	Scott Biller	Insider	Sell	5,500	$106.81	$587,455.00
3/2/2015	David P Schenkein	CEO	Sell	7,800	$107.05	$834,990.00
2/13/2015	David P Schenkein	CEO	Sell	1,471	$120.22	$176,843.62
2/13/2015	Glenn Goddard	SVP	Sell	1,316	$120.31	$158,327.96
2/11/2015	Glenn Goddard	SVP	Sell	16,513	$107.12	$1,768,872.56
2/9/2015	Glenn Goddard	SVP	Sell	15,000	$105.81	$1,587,150.00
2/2/2015	David P Schenkein	CEO	Sell	10,400	$114.31	$1,188,824.00
1/2/2015	David P Schenkein	CEO	Sell	13,000	$110.08	$1,431,040.00
1/2/2015	John Duncan Higgons	COO	Sell	12,000	$110.08	$1,320,960.00
1/2/2015	Scott Biller	Insider	Sell	4,500	$110.08	$495,360.00
12/16/2014	Celgene European Investment Co	Major Shareholder	Buy	228,645	$110.75	$25,322,433.75
12/16/2014	John Maraganore	Director	Buy	1,806	$110.75	$200,014.50
12/1/2014	David P Schenkein	CEO	Sell	13,000	$97.03	$1,261,390.00
12/1/2014	John Duncan Higgons	COO	Sell	12,000	$97.03	$1,164,360.00
12/1/2014	Scott Biller	Insider	Sell	4,500	$97.03	$436,635.00
11/3/2014	Glenn Goddard	SVP	Sell	2,000	$81.71	$163,420.00
11/3/2014	John Duncan Higgons	COO	Sell	13,000	$81.71	$1,062,230.00
11/3/2014	Scott Biller	Insider	Sell	4,500	$81.71	$367,695.00
10/1/2014	Glenn Goddard	SVP	Sell	1,500	$60.07	$90,105.00
10/1/2014	John Duncan Higgons	COO	Sell	13,000	$60.07	$780,910.00
10/1/2014	Scott Biller	Insider	Sell	4,500	$60.07	$270,315.00
9/26/2014	David P Schenkein	CEO	Sell	60,000	$62.68	$3,760,800.00
9/26/2014	Glenn Goddard	SVP	Sell	17,500	$56.53	$989,275.00
9/19/2014	Scott Biller	Insider	Sell	37,996	$50.45	$1,916,898.20
9/2/2014	Glenn Goddard	SVP	Sell	10,000	$46.30	$463,000.00
9/2/2014	John Duncan Higgons	COO	Sell	13,000	$46.30	$601,900.00
9/2/2014	Scott Biller	Insider	Sell	4,500	$46.30	$208,350.00
8/26/2014	John Duncan Higgons	COO	Sell	5,000	$45.05	$225,250.00
8/11/2014	David P Schenkein	CEO	Sell	4,530	$40.17	$181,970.10
7/1/2014	David P Schenkein	CEO	Sell	13,000	$46.52	$604,760.00
7/1/2014	Glenn Goddard	SVP	Sell	3,500	$46.52	$162,820.00
7/1/2014	John Duncan Higgons	COO	Sell	12,000	$46.52	$558,240.00
7/1/2014	Scott Biller	Insider	Sell	4,500	$46.52	$209,340.00
6/23/2014	John Maraganore	Director	Buy	2,300	$43.98	$101,154.00
6/20/2014	Scott Biller	Insider	Sell	2,004	$50.05	$100,300.20
6/13/2014	John Duncan Higgons	COO	Sell	5,000	$45.27	$226,350.00
6/3/2014	John Duncan Higgons	COO	Sell	7,000	$34.47	$241,290.00
5/6/2014	John Duncan Higgons	COO	Sell	5,000	$45.73	$228,650.00
5/1/2014	Glenn Goddard	SVP	Sell	2,000	$42.39	$84,780.00
5/1/2014	John Duncan Higgons	COO	Sell	7,000	$42.39	$296,730.00
5/1/2014	Scott Biller	Insider	Sell	4,500	$42.39	$190,755.00
4/29/2014	Celgene European Investment Co	major shareholder	Buy	294,800	$44.00	$12,971,200.00
4/29/2014	John Maraganore	Director	Buy	2,250	$44.00	$99,000.00
4/7/2014	Glenn Goddard	SVP	Sell	2,000	$45.17	$90,340.00
4/7/2014	John Duncan Higgons	COO	Sell	3,000	$45.17	$135,510.00
4/1/2014	Glenn Goddard	SVP	Sell	4,000	$38.08	$152,320.00
4/1/2014	John Duncan Higgons	COO	Sell	12,000	$38.08	$456,960.00
4/1/2014	Scott Biller	Insider	Sell	4,500	$38.08	$171,360.00
3/7/2014	Glenn Goddard	SVP	Sell	17,468	$42.11	$735,577.48
3/7/2014	John Duncan Higgons	COO	Sell	14,646	$41.41	$606,490.86
3/3/2014	John Duncan Higgons	COO	Sell	8,000	$29.85	$238,800.00
3/3/2014	Scott Biller	Insider	Sell	6,000	$29.85	$179,100.00
2/10/2014	Glenn Goddard	SVP	Sell	6,000	$30.44	$182,640.00
1/27/2014	Glenn Goddard	SVP	Sell	7,000	$26.29	$184,030.00
1/21/2014	Glenn Goddard	SVP	Sell	10,000	$34.71	$347,100.00
7/29/2013	Celgene European Investment Co	Major Shareholder	Buy	708,333	$18.00	$12,749,994.00

(Data available from 1/1/2013 forward)

Headline Trends for Agios Pharmaceuticals (NASDAQ:AGIO) Latest Headlines for Agios Pharmaceuticals (NASDAQ:AGIO)

Source:

Date	Headline
	Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : August 18, 2017 finance.yahoo.com - August 18 at 3:48 PM
	Agios Pharmaceuticals, Inc. (AGIO) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - August 18 at 12:48 PM
	See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc. finance.yahoo.com - August 14 at 9:02 PM
	Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y - Nasdaq www.nasdaq.com - August 11 at 4:07 PM
	Leerink Swann Comments on Agios Pharmaceuticals, Inc.'s FY2017 Earnings (NASDAQ:AGIO) www.americanbankingnews.com - August 11 at 12:02 PM
	Agios Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($1.78) Per Share, SunTrust Banks Forecasts (NASDAQ:AGIO) www.americanbankingnews.com - August 10 at 12:10 PM
	Q3 2017 Earnings Forecast for Agios Pharmaceuticals, Inc. Issued By Oppenheimer Holdings (NASDAQ:AGIO) www.americanbankingnews.com - August 10 at 12:10 PM
	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc. www.americanbankingnews.com - August 10 at 11:44 AM
	Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y finance.yahoo.com - August 9 at 3:49 PM
	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to Post FY2020 Earnings of $3.10 Per Share, Oppenheimer Holdings Forecasts www.americanbankingnews.com - August 9 at 3:02 PM
	Edited Transcript of AGIO earnings conference call or presentation 8-Aug-17 12:00pm GMT finance.yahoo.com - August 9 at 1:42 AM
	Agios Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release) globenewswire.com - August 8 at 8:37 PM
	Is a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season? - Nasdaq www.nasdaq.com - August 8 at 8:37 PM
	Agios (AGIO) Q2 Loss Wider than Expected; Sales Miss - Nasdaq www.nasdaq.com - August 8 at 8:37 PM
	Agios: Smooth First Mover In Cancer Metabolism - Seeking Alpha seekingalpha.com - August 8 at 8:37 PM
	Agios Pharmaceuticals, Inc. (AGIO) Given a $90.00 Price Target at Canaccord Genuity www.americanbankingnews.com - August 8 at 6:26 PM
	Agios Pharmaceuticals' (NASDAQ:AGIO) "Buy" Rating Reaffirmed at SunTrust Banks, Inc. www.americanbankingnews.com - August 8 at 5:44 PM
	BRIEF-Agios posts Q2 loss per share $1.78‍ www.reuters.com - August 8 at 3:34 PM
	Agios Pharmaceuticals, Inc. 2017 Q2 - Results - Earnings Call Slides seekingalpha.com - August 8 at 3:34 PM
	Agios Reports Second Quarter 2017 Financial Results finance.yahoo.com - August 8 at 3:34 PM
	Agios (AGIO) Q2 Loss Wider than Expected; Sales Miss finance.yahoo.com - August 8 at 3:34 PM
	Agios Pharmaceuticals reports 2Q loss finance.yahoo.com - August 8 at 3:34 PM
	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Posts Earnings Results, Misses Expectations By $0.21 EPS www.americanbankingnews.com - August 8 at 9:00 AM
	Is a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season? finance.yahoo.com - August 7 at 4:34 PM
	Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More finance.yahoo.com - August 7 at 4:34 PM
	4 Medical Product Stocks Likely to Top Q2 Earnings Estimates finance.yahoo.com - August 7 at 4:34 PM
	Brokerages Expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Will Post Quarterly Sales of $11.52 Million www.americanbankingnews.com - August 7 at 8:32 AM
	-$1.51 EPS Expected for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) This Quarter www.americanbankingnews.com - August 5 at 8:36 PM
	Agios Pharmaceuticals, Inc. (AGIO) Forecasted to Earn Q2 2017 Earnings of ($1.48) Per Share www.americanbankingnews.com - August 4 at 7:16 AM
	Agios Pharmaceuticals, Inc. (AGIO) Insider Sells $1,379,501.60 in Stock www.americanbankingnews.com - August 3 at 7:52 PM
	David P. Schenkein Sells 27,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock www.americanbankingnews.com - August 3 at 7:50 PM
	Agios Pharmaceuticals Reaches Analyst Target Price www.nasdaq.com - August 3 at 4:41 PM
	A small biotech behind a groundbreaking approach to tackling cancer just got its first drug approved - Business Insider www.businessinsider.com - August 3 at 4:41 PM
	Agios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session - Nasdaq www.nasdaq.com - August 3 at 4:41 PM
	Celgene CEO: Precision medicine targeting metabolic drive... finance.yahoo.com - August 3 at 4:41 PM
	Agios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session finance.yahoo.com - August 3 at 4:41 PM
	Agios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017 finance.yahoo.com - August 3 at 4:41 PM
	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given a $90.00 Price Target at Canaccord Genuity www.americanbankingnews.com - August 2 at 6:28 PM
	Benzinga's Top Upgrades, Downgrades For August 2, 2017 - Benzinga www.benzinga.com - August 2 at 3:32 PM
	This Small Biotech Launched To A 9-Month High Today — Here's Why finance.yahoo.com - August 2 at 3:32 PM
	A small biotech behind a groundbreaking approach to tackling cancer just got its first drug approved finance.yahoo.com - August 1 at 4:38 PM
	A small biotech behind a groundbreaking approach to tackling cancer just got its first drug approved finance.yahoo.com - August 1 at 4:38 PM
	Agios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017 - GlobeNewswire (press release) globenewswire.com - July 28 at 3:57 PM
	Agios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017 feeds.benzinga.com - July 28 at 8:32 AM
	Revlimid drives Celgene profit beat; raises EPS forecast finance.yahoo.com - July 27 at 3:49 PM
	Commit To Purchase Agios Pharmaceuticals At $45, Earn 10.9% Annualized Using Options - Nasdaq www.nasdaq.com - July 26 at 3:38 PM
	What's in Store for Agios Pharma (AGIO) in Q2 Earnings? finance.yahoo.com - July 26 at 3:38 PM
	Agios Pharmaceuticals, Inc. (AGIO) Scheduled to Post Quarterly Earnings on Wednesday www.americanbankingnews.com - July 26 at 7:12 AM
	Agios Pharmaceuticals, Inc. (AGIO) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - July 24 at 12:11 PM
	Agios Pharmaceuticals, Inc. (AGIO) Director Sells $196,490.00 in Stock www.americanbankingnews.com - July 21 at 7:31 PM